

1 **Hospital *Enterococcus faecium* demonstrates distinct environmental and patient reservoirs: a**
2 **genomic point prevalence survey**

3 Nenad Macesic^{*1,2,3}, Hugh Cottingham¹, Jessica A. Wisniewski¹, Luke V. Blakeway¹, Ravali
4 Theegala¹, Katherine Pragastis¹, Andrew Stewardson^{1,2}, Pauline Bass², Megan Gritt², Stephanie
5 Spilsbury², Denise Del Rosario-Kelly², Amanda Dennison⁴, Denis W. Spelman^{1,4}, Adam W.J.
6 Jenney^{1,4}, Anton Y. Peleg^{*1,3,5}

7
8 ¹ Department of Infectious Diseases, The Alfred Hospital and School of Translational Medicine,
9 Monash University, Melbourne, Australia

10 ² Infection Prevention & Healthcare Epidemiology, Alfred Health, Melbourne, Australia.

11 ³ Centre to Impact AMR, Monash University, Clayton, Australia

12 ⁴ Microbiology Unit, Alfred Health, Melbourne, Australia.

13 ⁵ Infection Program, Monash Biomedicine Discovery Institute, Department of Microbiology, Monash
14 University, Clayton, Australia

15

16 * Joint Corresponding Authors

17 Dr. Nenad Macesic, Department of Infectious Diseases, The Alfred Hospital and School of
18 Translational Medicine, Monash University, Level 1 Alfred Lane House, Alfred Hospital, 55
19 Commercial Rd, Melbourne, VIC 3004, Australia. Email: nenad.macesic1@monash.edu

20

21 Professor Anton Y. Peleg, Department of Infectious Diseases, The Alfred Hospital and School of
22 Translational Medicine, Monash University, Level 1 Alfred Lane House, Alfred Hospital, 55
23 Commercial Rd, Melbourne, VIC 3004, Australia. Email: anton.peleg@monash.edu

24

25 Word count: 1200 words

26

27 **Abstract**

28

29 **Objectives**

30 *Enterococcus faecium* is a common cause of hospital-acquired infections and is associated with
31 vancomycin resistance. The hospital environment is often a reservoir for *E. faecium* due to its ability
32 to survive on surfaces. In 2019 we noted increasing prevalence of *vanA E. faecium* causing
33 bloodstream infections. We aimed to assess the hospital environment as a reservoir of *vanA E.*
34 *faecium*.

35

36 **Methods**

37 We conducted a point prevalence survey of the environment at the Alfred Hospital, Melbourne,
38 Australia. We sampled all wards (n=12), 10 surface types and 357 surfaces. Resulting *E. faecium*
39 isolates underwent short-read whole genome sequencing and were compared to invasive infection
40 (bloodstream) isolates. The *van* operon, multi-locus sequence type (MLST) and core genome MLST
41 (cgMLST) were determined.

42

43 **Results**

44 Twenty percent (73/357) of surfaces isolated *E. faecium* with a median of 20% positivity per ward
45 (IQR 11.6-30.6%). *vanA* and *vanB* were detected in 12/73 (16%) and 58/73 (79%) environmental
46 genomes, respectively. In contrast, a higher proportion of bloodstream isolates carried *vanA* (32/72
47 [44%], $P<0.001$). Environmental genomes belonged to 10 MLSTs and 10 cgMLSTs, with ST796/ST78
48 accounting for 54/73 (74%) genomes. Clinical STs and cgMLSTs overlapped with environmental but
49 were more diverse. We noted 13 putative genomic transmission clusters. One cluster contained 25/44
50 (57%) *vanA* genomes, with the majority being clinical (22/26 genomes, 85%). Environmental-clinical
51 links were observed in 292/895 (33%) putative genomic transmission links. In completed assemblies,
52 the *vanA* and *vanB* operons were located on pRE25-like plasmids and the chromosome, respectively.

53

54 **Conclusion**

55 We noted a 20% prevalence of *E. faecium* environmental colonisation but the *vanA* operon was
56 detected in only 12/73 genomes. We identified distinct environmental and patient reservoirs, with

57 most environmental genomes carrying the *vanB* operon and having distinct STs/cgMLST clusters.

58 Environment-clinical reservoir spillover was detected but accounted for a minority of putative

59 transmission links.

60

61 **Introduction**

62 *Enterococcus faecium* is a common cause of hospital-acquired infections and is frequently associated
63 with vancomycin resistance [1], resulting in high mortality, longer hospital stays and higher healthcare
64 costs [2]. The hospital environment is a reservoir for *E. faecium* due to its ability to survive on
65 surfaces for prolonged periods [1]. Prior studies have analysed patient and environmental reservoirs
66 of *E. faecium* but have typically been limited to selected hospital wards in settings where either *vanA*
67 or *vanB* vancomycin-resistant *E. faecium* (VREfm) predominate [3-5]. Australia has a specific VREfm
68 epidemiology with more recent emergence of *vanA* VREfm on a background of *vanB* VREfm
69 endemicity, with both continuing to circulate [6]. In 2019, we noted increasing prevalence of *vanA*
70 VREfm bloodstream infections. We aimed to assess the hospital environment as a reservoir of *vanA*
71 VREfm by conducting a point prevalence study and comparing environmental and contemporary
72 clinical isolates using genomic analyses.

73

74 **Methods**

75 The study was approved by the Alfred Hospital Ethics Committee. The Alfred Hospital (Melbourne,
76 Australia) is a 600-bed quaternary hospital with state referral services for burns and trauma, as well
77 as stem cell and solid organ (heart/lung/kidney) transplant services. We conducted a point prevalence
78 survey of the hospital environment. We sampled surfaces using FLOQswabs (Copan) over two
79 months, which included all wards and the intensive care unit (ICU) (n=12), with 10 surface types
80 sampled per ward/ICU. Samples were cultured on CHROMagar VRE media (Biomérieux) and species
81 were identified using matrix-assisted laser desorption-ionisation time-of-flight (MALDI-TOF) (Bruker
82 Daltonics). To assess for molecular epidemiological links between environmental and clinical isolates,
83 we selected all *E. faecium* blood culture isolates from our established biobank from 6 months prior to
84 6 months post the environmental sampling (Supp. Figure 1 and Supp. Table 1). Clinical data were
85 extracted from the electronic medical record.

86

87 All *E. faecium* isolates underwent short-read (Illumina) whole genome sequencing, as described
88 previously [7]. We detected *van* operon presence and assigned multi-locus sequence type (MLST)
89 and core genome MLST (cgMLST) [8]. For each cgMLST cluster, we assembled a long-read

90 reference genome and calculated within-cluster pairwise single nucleotide variant (SNV) distances.
91 Please see Supplementary Methods for full details.

92

93 **Results**

94 *Environmental point prevalence survey*

95 We swabbed 357 surfaces (median 31.5 per ward [range 10-60]). A total of 73/357 (20%) surfaces
96 isolated *E. faecium*, with median 20% positive per ward (IQR 11.6-30.6%) (Fig. 1A), indicating that *E.*
97 *faecium* was endemic in the hospital environment. Rates of *E. faecium* positivity varied widely, with
98 the highest rate in the Burns ward (10/10 swabs positive) and the lowest rate on Surgical Ward 3
99 (0/34 positive). Patient chairs had the highest rate of *E. faecium* positivity (13/25 [52%]) (Fig. 1B).

100

101 *Environmental and clinical genome characteristics*

102 All 72 *E. faecium* blood culture isolates that occurred in the 6 months pre- and post-environmental
103 sampling were sequenced and compared to the 73 positive environmental swabs (Fig. 1C, Supp Fig.
104 1). *vanA* and *vanB* were detected in 12/73 (16%) and 58/73 (79%) environmental genomes,
105 respectively (Fig. 1C). In contrast, 32/72 (44%) clinical genomes carried *vanA* ($P<0.001$) and 31/72
106 (43%) carried *vanB*. Environmental genomes belonged to 10 MLSTs and 10 cgMLSTs, with
107 ST796/ST78 accounting for 54/73 (74%) genomes (Fig. 1C, 1D). Clinical STs/cgMLSTs overlapped
108 with environmental genomes but were more diverse. Specifically, ST1421/1424 carried *vanA* and
109 were more frequent in clinical genomes (30/72 v 7/73 genomes, $P<0.001$). A single cgMLST cluster
110 (B) contained the majority of *vanA* genomes (25/44 genomes), while *vanB* genomes were noted
111 across two cgMLST clusters (A and C, 84/89 genomes) (Fig. 1D). STs/cgMLSTs carried either *vanA*
112 or *vanB* operons, except for 3 genomes in ST796/cgMLST cluster A that had concurrent *vanA* and
113 *vanB* carriage (Fig. 1C/1D).

114

115 *Geography of E. faecium on hospital wards*

116 We mapped *E. faecium* ST/cgMLST and presence of *van* operon across individual wards (Supp. Fig.
117 2). High-risk wards (ICU, Haematology/Oncology) had the majority of clinical genomes with a resultant
118 high diversity of STs/cgMLSTs (7 STs/10cgMLSTs for Haematology/Oncology and 7 STs/7 cgMLSTs
119 for ICU, respectively). The Haematology/Oncology ward had the highest proportion of *vanA* genomes

120 (12/25, 48%), with 7/12 of these being ST1424/cgMLST cluster B genomes. Other wards had uniform
121 ST/cgMLST composition with no differences between wards (Supp. Fig. 2).

122

123 *E. faecium* transmission networks

124 Using a 6 SNV cutoff [4], there were 895 putative genomic transmission links resulting in 13 clusters
125 (Fig. 2). While 292/895 (33%) links were environmental-clinical, of these only 88/292 (30%) were
126 between *vanA* genomes. Most clusters had a predominance of either environmental-environmental
127 links or clinical-clinical links (Supp. Table 2). A single cluster contained 25/44 (57%) *vanA* genomes,
128 with the majority being clinical (22/26, 85%). Environmental genomes in that cluster came from three
129 wards, while clinical genomes came from 11 wards. In contrast, *vanB* genomes belonged to three
130 major (>5 genomes) clusters, containing predominantly environmental genomes (42/56, 75%).

131

132 *van* operon analysis

133 In completed assemblies (n=26), the *vanA* and *vanB* operons were located on pRE25-like plasmids
134 and the chromosome, respectively. The pRE25-like plasmids were heterogeneous and did not
135 indicate spread of a single plasmid across multiple cgMLST clusters (Supp. Figure 3).

136

137 Discussion

138 We noted a 20% prevalence of *E. faecium* environmental colonisation across a diverse range of
139 hospital surfaces, but only 12/73 (17%) environmental genomes carried *vanA*. This indicated that
140 while *E. faecium* was endemic in the hospital environment, it likely did not make a major contribution
141 to the increased *vanA* VREfm prevalence in bloodstream infection isolates. Indeed, we noted distinct
142 environmental and patient reservoirs: an environment dominated by *vanB* ST796/78 genomes, and a
143 clinical reservoir comprising *vanA* ST1421/1424 genomes. There was evidence of spill-over with
144 putative clinical-environmental links, but these were a minority (33%) and *vanA* putative genomic links
145 only contributed 88/895 (10%) of these in turn.

146

147 Our findings stand in contrast to prior work showing significant links between VREfm in the
148 environment and clinical colonisation and infection [3-5]. This difference may be due to these studies
149 describing non-outbreak settings and focusing on limited wards (ICU and Haematology/Oncology).

150 Potential contributors to our findings include our institution's differing infection prevention approaches
151 to *vanA* and *vanB* VREfm-colonised patients [9]: *vanA* patients are routinely placed in contact
152 precautions, while for *vanB* patients this occurs only on high-risk wards and if they have diarrhoea or
153 non-contained wounds. *E. faecium* ST796, a key *vanB* lineage in our study, has been shown to
154 develop biocide tolerance that may provide it with a fitness advantage in hospital environments [10].
155 Of note, the *vanA* clinical reservoir that prompted our investigation subsequently resolved during the
156 COVID-19 pandemic (Supp. Fig. 1), perhaps because of these factors.

157

158 Although the environment plays a major role in healthcare-associated VREfm spread, our study
159 shows that distinct clinical and environmental reservoirs of VREfm may exist, particularly in outbreak
160 settings where new clones are emerging and have not yet colonised the environment. This provides
161 support for use of molecular techniques to focus infection prevention strategies according to the
162 reservoir. While cleaning strategies aiming to reduce the environmental burden form an essential part
163 of any multifaceted approach to VREfm control [11], the clinical reservoir may require more active
164 attention through measures such as introduction of active surveillance, redoubled hand hygiene
165 efforts and more stringent application of contact precautions in order to prevent both between-patient
166 spread and future environmental colonisation.

167

168 **Conflict of Interest Statements**

169 Nil relevant.

170

171 **Role of Funding Source**

172 This work was supported by the National Health and Medical Research Council of Australia

173 (Emerging Leader 1 Fellowship APP1176324 to N.M., Practitioner Fellowship APP1117940 to

174 A.Y.P.).

175

176 The funders had no role in study design, data collection and interpretation, or the decision to submit

177 the work for publication.

178

179 **Conference Presentation**

180 Portions of this work were presented at European Society of Clinical Microbiology and Infectious

181 Diseases (ESCMID) Global 2024, held in Barcelona, Spain.


182

183 References

- 184 [1] X. Zhou, R.J.L. Willems, A.W. Friedrich, J.W.A. Rossen, E. Bathoorn, Enterococcus faecium: from
185 microbiological insights to practical recommendations for infection control and diagnostics, *Antimicrob*
186 *Resist Infect Control* 9(1) (2020) 130.
- 187 [2] M. Serra-Burriel, M. Keys, C. Campillo-Artero, A. Agodi, M. Barchitta, A. Gikas, C. Palos, G. López-
188 Casasnovas, Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcare-
189 associated infections in adults: Systematic review and meta-analysis, *Plos One* 15(1) (2020)
190 e0227139.
- 191 [3] L. El Haddad, B.M. Hanson, C.A. Arias, S.S. Ghantaji, C.P. Harb, M. Stibich, R.F. Chemaly,
192 Emergence and Transmission of Daptomycin and Vancomycin-Resistant Enterococci Between
193 Patients and Hospital Rooms, *Clin Infect Dis* 73(12) (2021) 2306-2313.
- 194 [4] T. Gouliouris, F. Coll, C. Ludden, B. Blane, K.E. Raven, P. Naydenova, C. Crawley, M.E. Torok,
195 D.A. Enoch, N.M. Brown, E.M. Harrison, J. Parkhill, S.J. Peacock, Quantifying acquisition and
196 transmission of Enterococcus faecium using genomic surveillance, *Nat Microbiol* 6(1) (2021) 103-111.
- 197 [5] A.S. Lee, E. White, L.G. Monahan, S.O. Jensen, R. Chan, S.J.v. Hal, Defining the Role of the
198 Environment in the Emergence and Persistence of vanA Vancomycin-Resistant Enterococcus (VRE)
199 in an Intensive Care Unit: A Molecular Epidemiological Study, *Infect. Control Hosp. Epidemiology*
200 39(6) (2018) 668-675.
- 201 [6] G.W. Coombs, D.A. Daley, P. Shoby, S. Mowlaboccus, Australian Group on Antimicrobial
202 Resistance (AGAR) Australian Enterococcal Surveillance Outcome Program (AESOP), *Commun Dis*
203 *Intell* (2018) 46 (2022).
- 204 [7] N. Macesic, J. Hawkey, B. Vezina, J.A. Wisniewski, H. Cottingham, L.V. Blakeway, T. Harshegyi, K.
205 Pragastis, G.Z. Badoordeen, A. Dennison, D.W. Spelman, A.W.J. Jenney, A.Y. Peleg, Genomic
206 dissection of endemic carbapenem resistance reveals metallo-beta-lactamase dissemination through
207 clonal, plasmid and integron transfer, *Nat. Commun.* 14(1) (2023) 4764.
- 208 [8] C. Higgs, N.L. Sherry, T. Seemann, K. Horan, H. Walpola, P. Kinsella, K. Bond, D.A. Williamson, C.
209 Marshall, J.C. Kwong, M.L. Grayson, T.P. Stinear, C.L. Gorrie, B.P. Howden, Optimising genomic
210 approaches for identifying vancomycin-resistant Enterococcus faecium transmission in healthcare
211 settings, *Nat Commun* 13(1) (2022) 509.
- 212 [9] D.J. Morgan, R. Murthy, L.S. Munoz-Price, M. Barnden, B.C. Camins, B.L. Johnston, Z. Rubin, K.V.
213 Sullivan, A.L. Shane, E.P. Dellinger, M.E. Rupp, G. Bearman, Reconsidering contact precautions for
214 endemic methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus, *Infect*
215 *Control Hosp Epidemiol* 36(10) (2015) 1163-72.
- 216 [10] S.J. Pidot, W. Gao, A.H. Buultjens, I.R. Monk, R. Guerillot, G.P. Carter, J.Y.H. Lee, M.M.C. Lam,
217 M.L. Grayson, S.A. Ballard, A.A. Mahony, E.A. Grabsch, D. Kotsanas, T.M. Korman, G.W. Coombs,
218 J.O. Robinson, A. Gonçalves da Silva, T. Seemann, B.P. Howden, P.D.R. Johnson, T.P. Stinear,
219 Increasing tolerance of hospital Enterococcus faecium to handwash alcohols, *Sci Transl Med* 10(452)
220 (2018).
- 221 [11] G. De Angelis, M.A. Cataldo, C. De Waure, S. Venturiello, G. La Torre, R. Cauda, Y. Carmeli, E.
222 Tacconelli, Infection control and prevention measures to reduce the spread of vancomycin-resistant
223 enterococci in hospitalized patients: a systematic review and meta-analysis, *J Antimicrob Chemother*
224 69(5) (2014) 1185-92.
- 225

226
227
228


Figure 1 – Summary of *Enterococcus faecium* environmental screening and contemporary clinical isolates



229
230
231
232
233
234

A) Proportion of environmental screening swabs positive for *E. faecium* by ward and **B)** by surface type. **C)** Summary of *E. faecium* *van* operon presence by multi-locus sequence types (MLST) and **D)** core genome MLST (cgMLST) in clinical and environmental isolates.

235 **Figure 2 – Network analysis of *Enterococcus faecium* putative genomic transmission links**
236



237
238
239
240
241
242
243
244

Clinical and environmental *E. faecium* genomes are shown as nodes and putative genomic transmission events (defined as pairwise single nucleotide variant distance ≤ 6) as edges. Edges resulting from clinical-environmental links are shown in black, and clinical-clinical or environmental-environmental in grey. A single major *vanA* cluster is noted with majority of clinical genomes. In contrast, three major *vanB* clusters are noted with environmental genomes predominating.